Dogecoin Cash, INC 10-Q quarterly reports

Dogecoin Cash, Inc. reported a 5% increase in revenue for Q1 2026, but a significant surge in operating expenses led to a wider net loss compared to the prior year.

Dogecoin Cash, Inc. reported a significant net loss for the nine months ended September 30, 2025, primarily driven by a substantial impairment of its Dogecoin Cash tokens, despite some operational improvements.

Dogecoin Cash, Inc. reported a substantial increase in net loss for Q2 2025, primarily driven by a significant impairment of its Dogecoin Cash token investments, alongside declining revenue from its cannabis tele-medicine operations.

Dogecoin Cash, Inc. files an amendment to its Q1 2025 report to include previously omitted XBRL data, while also reporting a decrease in revenue and a net loss for the quarter.

Dogecoin Cash, Inc. reports an 18% decrease in revenue for the quarter ended March 31, 2025, primarily due to increased competition in the cannabis telemedicine industry, alongside ongoing concerns about its ability to continue as a going concern.

Dogecoin Cash, Inc. has filed an amendment to its quarterly report to correct an omission related to a share issuance that occurred after the reporting period.

Dogecoin Cash, Inc., formerly Cannabis Sativa, Inc., experienced a 31% decrease in revenue for the nine months ended September 30, 2024, primarily due to heightened competition in the cannabis telemedicine market.

Cannabis Sativa Inc. experienced a 27% decrease in revenue for the second quarter of 2024 compared to the same period last year, primarily due to heightened competition in the cannabis telemedicine market.

Cannabis Sativa Inc. experienced a 35% decrease in revenue during the first quarter of 2024 compared to the same period last year, primarily due to heightened competition in the cannabis telemedicine market.